doi: 10.1128/AAC.30.1.189.
Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon
- PMID: 3019235
- PMCID: PMC176465
- DOI: 10.1128/AAC.30.1.189
Item in Clipboard
Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon
Antimicrob Agents Chemother.
1986 Jul.
Abstract
Phosphonoformate and recombinant alpha-A interferon synergistically inhibited the replication of human T-cell lymphotropic virus type III in cultured peripheral blood lymphocytes. T-cell proliferative capability was maintained by this combination, and toxicity was minimal.
Similar articles
-
Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.Lancet. 1985 Jun 29;1(8444):1480-2. doi: 10.1016/s0140-6736(85)92255-x. Lancet. 1985. PMID: 2409414
-
Inhibition of HTLV-III/LAV replication by foscarnet.Biochem Pharmacol. 1985 Nov 15;34(22):4075-9. doi: 10.1016/0006-2952(85)90392-2. Biochem Pharmacol. 1985. PMID: 2415134 No abstract available.
-
In vitro inhibition of Herpesvirus sylvilagus by phosphonoacetic acid and phosphonoformate.Arch Virol. 1980;66(3):261-4. doi: 10.1007/BF01314739. Arch Virol. 1980. PMID: 6449917
-
Antiviral effects of phosphonoformate (PFA, foscarnet sodium).Pharmacol Ther. 1982;19(3):387-415. doi: 10.1016/0163-7258(82)90074-2. Pharmacol Ther. 1982. PMID: 6201932 Review. No abstract available.
-
Prospects of therapy for infections with human T-lymphotropic virus type III.Ann Intern Med. 1985 Nov;103(5):750-5. doi: 10.7326/0003-4819-103-5-750. Ann Intern Med. 1985. PMID: 2413793 Review.
Cited by
-
Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay.J Clin Microbiol. 1988 Feb;26(2):231-5. doi: 10.1128/jcm.26.2.231-235.1988. J Clin Microbiol. 1988. PMID: 3422647 Free PMC article.
-
Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro.Antimicrob Agents Chemother. 1987 Jul;31(7):1046-50. doi: 10.1128/AAC.31.7.1046. Antimicrob Agents Chemother. 1987. PMID: 2444155 Free PMC article.
-
Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.Drugs. 1991 Jan;41(1):104-29. doi: 10.2165/00003495-199141010-00009. Drugs. 1991. PMID: 1706982 Review.
-
Antiviral therapy for human immunodeficiency virus infections.Clin Microbiol Rev. 1995 Apr;8(2):200-39. doi: 10.1128/CMR.8.2.200. Clin Microbiol Rev. 1995. PMID: 7542558 Free PMC article. Review.
-
Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.Antimicrob Agents Chemother. 1989 May;33(5):778-80. doi: 10.1128/AAC.33.5.778. Antimicrob Agents Chemother. 1989. PMID: 2526616 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
